Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-Year follow-up

Urology

Volumn 61, Issue 2, 2003, Pages 354-358

  Lam, John S ^a   Romas, Nicholas A ^a   Lowe, Franklin C ^a,b  

^a S Luke's Roosevelt Hospital Center ^*  (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE;

ADULT; AGED; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RECTUM; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0037319346     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02149-0     Document Type: Article

References (19)

1. Berry S.J., Coffey D.S., Walsh P.C., et al. The development of human benign prostatic hyperplasia with age. J Urol. 132:1984;474-479.
2. Oesterling J.E. Benign prostatic hyperplasia medical and minimally invasive treatment options . N Engl J Med. 332:1995;99-109.
3. Roehrborn C.G., Oesterling J.E., Auerbach S., et al. for the HYCAT Investigator Group: The Hytrin Community Assessment Trial study a one-year study of terazosin verus placebo in the treatment of men with symptomatic benign prostatic hyperplasia . Urology. 47:1996;159-168.
4. Elhilali M.M., Ramsey E.W., Barkin J., et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology. 47:1996;335-342.
5. Lepor H., Kaplan S.A., Klimberg I., et al. for the Multicenter Study Group: Doxazosin for benign prostatic hyperplasia long-term efficacy and safety in hypertensive and normotensive patients . J Urol. 157:1997;525-530.
6. Lepor H. for the Tamsulosin Investigator Group: Long-term evaluation of tamsulosin in benign prostatic hyperplasia placebo-controlled, double-blind extension of phase III trial . Urology. 51:1998;901-906.
7. Gormley G.J., Stoner E., Bruskewitz R.C., et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1992;1185-1191.
8. Nickel J.C., Fradet Y., Boake R.C., et al. for the PROSCAR Safety Plus Efficacy Canadian Two Year Study. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia results of a 2-year randomized controlled trial (the PROSPECT study) . Can Med Assoc J. 155:1996;1251-1259.
9. Bartsch G., Rittmaster R.S., Klocker H. Dihydrotestosterone and the concept of 5 alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol. 37:2000;367-380.
10. Vermeulen A., Giagulli V.A., Schepper P.D., et al. Hormonal effects of an orally active 4-azasteroid inhibitor or 5 alpha reductase in humans. Prostate. 14:1989;45-53.
11. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate. 22:1993;291-299.
12. Liang T., Heiss C.E., Cheung A.H., et al. 4-Azasteriodfra-reductase inhibitors without affinity for the androgen receptor. J Biochem. 259:1984;734-739.
13. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338:1998;557-563.
14. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 43:1994;284-294.
15. Stoner E. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. J Urol. 147:1992;1298-1302.
16. Andersen J.T., Ekman P., Wolf H., et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo controlled study. Urology. 46:1995;631-637.
17. Hudson P.B., Boake R., Trachtenberg J., et al. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. Urology. 53:1999;690-695.
18. Andersen J.T., Nickel J.C., Marshal V.R., et al. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology. 49:1997;839-845.
19. Boyle P., Gould A.L., Roehrborn C.G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride meta-analysis of randomized clinical trials . Urology. 48:1996;398-405.